Add-on Acquisition • Life Science

Boston Therapeutics Acquires CureDM

On February 13, 2018, Boston Therapeutics acquired life science company CureDM

Acquisition Context

This is Boston Therapeutics’ 1st transaction in the Life Science sector.
This is Boston Therapeutics’ 1st transaction in the United States.
This is Boston Therapeutics’ 1st transaction in Delaware.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	February 13, 2018
Target	CureDM
Sector	Life Science
Buyer(s)	Boston Therapeutics
Deal Type	Add-on Acquisition

Target Company

CureDM

Wilmington, Delaware, United States

CureDM, Inc. is a clinical development of the novel peptide therapeutic, HIP2B, for the treatment of type 1 and type 2 diabetes. CureDM is based in Wilmington, Delaware.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Boston Therapeutics

Lawrence, Massachusetts, United States

Category	Company
Sector	Life Science
Revenue	99M USD (2015)

DESCRIPTION

Boston Therapeutics, Inc. is a designer, developer and commercialization of compounds, such as investigational BTI-320, to treat diabetes and diabetes related complications. Boston Therapeutics is based in Lawrence, Massachusetts.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: Delaware	1 of 1
Country: United States	1 of 1
Year: 2018	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Delaware M&A - United States M&A - 2018 M&A